Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2025)

Historic FCF Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 43.42%.

  • Maravai Lifesciences Holdings' FCF Margin fell 500100.0% to 43.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.47%, marking a year-over-year decrease of 306000.0%. This contributed to the annual value of 8.56% for FY2024, which is 295600.0% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its FCF Margin stood at 43.42% for Q3 2025, which was down 500100.0% from 27.72% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' FCF Margin's 5-year high stood at 97.7% during Q1 2023, with a 5-year trough of 43.42% in Q3 2025.
  • For the 5-year period, Maravai Lifesciences Holdings' FCF Margin averaged around 17.67%, with its median value being 11.35% (2024).
  • In the last 5 years, Maravai Lifesciences Holdings' FCF Margin skyrocketed by 558700bps in 2021 and then crashed by -1197200bps in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' FCF Margin (Quarter) stood at 23.24% in 2021, then skyrocketed by 96bps to 45.49% in 2022, then plummeted by -127bps to 12.15% in 2023, then crashed by -198bps to 36.22% in 2024, then dropped by -20bps to 43.42% in 2025.
  • Its FCF Margin was 43.42% in Q3 2025, compared to 27.72% in Q2 2025 and 31.22% in Q1 2025.